Clin Psychopharmacol Neurosci.  2018 Nov;16(4):434-448. 10.9758/cpn.2018.16.4.434.

Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision

  • 1Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • 2Department of Psychiatry, Inje University Haeundae Paik Hospital, Inje University College of Medicine and Paik Institute for Clinical Research, Busan, Korea.
  • 3Department of Health Science and Technology, Graduate School of Inje University, Busan, Korea.
  • 4Department of Psychiatry, Jeju National University Hospital, Jeju, Korea.
  • 5Department of Psychiatry, Keyo Hospital, Keyo Medical Foundation, Uiwang, Korea.
  • 6Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.
  • 7Department of Psychiatry, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
  • 8Department of Psychiatry, School of Medicine, Konkuk University, Chungju, Korea.
  • 9Department of Psychiatry, Chung-Ang University College of Medicine, Seoul, Korea.
  • 10Department of Psychiatry, Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea.
  • 11Department of Psychiatry, Myongji Hospital, Goyang, Korea.
  • 12Department of Psychiatry, Naju National Hospital, Naju, Korea.


The Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) was first published in 2002 through an expert consensus of opinion, and updated in 2006, 2010, and 2014. This study constitutes the fourth revision of the KMAP-BP.
A 50-item questionnaire was used to obtain the consensus of experts regarding pharmacological treatment strategies for various phases of adult bipolar disorder and six items for pediatric bipolar disorder. The review committee included 84 Korean psychiatrists and 43 child and adolescent psychiatry experts.
The preferred first-step strategies for acute mania were the combination of a mood stabilizer (MS) and an atypical antipsychotic (AAP), MS monotherapy, and AAP monotherapy. A combination of a MS and an AAP, and AAP monotherapy were preferred for psychotic mania. The first-step strategies for mild to moderate bipolar depression were monotherapy with MS, AAP, or lamotrigine (LMT), and the combination of a MS and an AAP or LMT, or a combination of an AAP and LMT. The combination of two among a MS, AAP, and LMT were preferred for non-psychotic severe depression. A combination of a MS and an AAP or the combination of an AAP with an antidepressant or LMT were the first-line options for psychotic severe depression.
The recommendations of the KMAP-BP 2018 have changed from the previous version by reflecting recent developments in pharmacotherapy for bipolar disorder. KMAP-BP 2018 provides clinicians with a wealth of information regarding appropriate strategies for treating patients with bipolar disorder.


Bipolar disorder; Expert consensus; Drug therapy; Practice guideline
Full Text Links
  • CPN
  • Twitter
  • Facebook
Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: